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WS5.1 Improving the annual review process − the rainbow project
P. Yarrow1, R. Hollin1, J. Chawla1. 1Mater Childrens Hospital, Department
Respiratory and Sleep Medicine, South Brisbane, Australia
Background: The CF Foundation encourages CF centres to undertake local projects
with the aim of improving CF Care. In 2012 a retrospective audit of the CF Annual
Review (AR) process at Mater Children’s Hospital (MCH) was conducted. Whilst
the percentage of ARs completed was found to be high, it was recognised that the
vast amount of patient information being obtained was being underutilised.
Aims:
a. To increase the AR completion rate.
b. To ensure that 100% of ARs have ﬁnalised documentation.
c. To ensure all AR are discussed by the multi-disciplinary team (MDT).
Methods: A new system was developed. A colour-coded spread sheet was used
allowing easy identiﬁcation of the point at which the patient had reached in the AR
process; hence termed ‘the rainbow project’. Collected information was presented
weekly at the CF MDT meeting. A proposed plan for each patient was discussed and
speciﬁc goals for the following year agreed by the MDT. AR letters were ﬁnalised
following discussion and reviewed with families when next seen.
Results: A review was undertaken 6-months after commencement and demonstrated
successful introduction of the process. 100% of patients undergoing an AR were
discussed by the MDT with the identiﬁcation of speciﬁc goals for the following
year. Additionally, in all cases an AR letter was sent to both the GP and family.
Conclusion: Improved adherence was seen with the new system. We speculate that
reﬁnement of the AR process has led to improvements in CF care delivered at our
centre. A further audit is currently underway to assess this.
WS5.2 Travelling abroad with cystic ﬁbrosis (CF): current practice
and problems
S. Lenaghan1, L. Blanch1, S. Bourke1, S. Doe1, M. Caraher1, A. Anderson1.
1Royal Victoria Inﬁrmary, Newcastle Upon Tyne, United Kingdom
Objectives: Patients with CF are increasingly undertaking travel abroad. Recom-
mendations have been published (J Cyst Fibros 2010; 9: 385) but there are limited
data on the travel practices of patients and the problems encountered.
Methods: We undertook a structured interview of 100 patients (53 men, age
17−56 years, FEV1 18–128% pred).
Results: 96% had travelled abroad; 84% within the last 5 years with 75% travelling
often, to Europe and worldwide. 14% now limit travel for health reasons: 6 awaiting
lung transplant, 6 had advanced lung disease with frequent exacerbations and 2 had
other problems. Of those travelling recently 18% did not get insured and 23%
had insurance not covering CF. Many limited travel to Europe and relied on the
Eur Health Insurance Card. 25% were subjected to delays and extra searches at
airport security due to medications and nebulizer equipment. Medical certiﬁcates
helped but there were sometimes language problems. Many patients reduced/stopped
physiotherapy, nebulized treatments and nutritional supplements abroad; 44% used
nebulized therapies abroad, some having issues around sterilizing equipment and
storing DNase. 10 patients experienced a CF-related illness when abroad (7 chest
infection, 2 dehydration, 1 pancreatitis), 6 consulted a doctor and 3 had a brief
hospital admission; 12 had a non-CF illness abroad (4 sunburn, 4 gastroenteritis, 3
ear infections and 1 fall), and 2 had a brief attendance at a hospital.
Conclusion: Patients with CF travel often and widely. Travel insurance is a key
issue. Some patients with advanced disease prudently avoid travel. Serious medical
problems are rare in those travelling with the approval of their medical team.
WS5.3 Improving care for adults with end stage cystic ﬁbrosis at
Bristol Adult CF Centre (BACFC)
C. Addy1, N.J. Bell1, K. Bateman1. 1University Hospitals Bristol NHS Trust,
Bristol Adult Cystic Fibrosis Centre, Bristol, United Kingdom
Objectives: Managing end stage disease in CF remains challenging. Patients
experience high symptom burden, protracted disease course and need to consider
lung transplant. Most patients consider end of life care but few discuss it with their
CF team (Sawicki et al., 2008). Our aim was to improve care of patients with end
stage disease through review of previous care.
Methods: Retrospective analysis of deaths from 2007−13 and review of all current
patients with end stage disease (FEV1<30%/considering transplant) was performed.
Results: In the deceased group (n = 17), 94% had end of life discussions. 63% died
in hospital, 31% at home, 1 at a hospice. Mean duration from 1st discussion to
death was 282 days (range 1–1095 days). 3 deaths were sudden. Mean age at
death was 31 yrs, mean FEV1 24%. 38% of patients accepted psychology support.
4 patients were on lung transplant list, 1 being assessed, 1 post-transplant. Palliative
care reviewed 25% patients. Bereavement support was offered to 50% of families.
In end stage disease group (n = 18), mean age is 26 yrs, mean FEV1 24%. 3 patients
are on lung transplant list, 3 being assessed, 1 post-transplant. 58% have so far
discussed end of life care with 32% having a ‘do not resuscitate’ decision agreed.
82% accepted psychology support.
Over 50% patients suffer >5 symptoms daily; most commonly dyspnoea, pain
and secretions. Anxiety (51%) and depression (40%) had a high prevalence.
86% of patients required oxygen and non-invasive ventilation in 40%.
Conclusion: Providing palliative care for CF patients presents unique challenges.
To improve care we introduced Palliative care guidelines, annual review changes
and increased staff education.
WS5.4 Can registry data be used to examine cystic ﬁbrosis (CF)
health service utilisation? Perspectives of the Irish CF Registry
A. Jackson1, E. Suthoff2, G. Fletcher1, C. Kelleher3, M. Harrington1, S. Zhou1,
E. McKone4. 1Cystic Fibrosis Registry of Ireland, Dublin, Ireland; 2Vertex
Pharmaceuticals Incorporated, Boston, United States; 3University College Dublin,
School of Public Health, Physiotherapy and Population Science, Dublin, Ireland;
4St. Vincent’s University Hospital, Dublin, Ireland
CF registries provide data that contributes to better management of health resources,
evaluation of care services policies and development of care accreditation processes.
In this study, we examine patterns in CF service usage, using data from the Irish
CF Registry.
A cross-sectional, population based analysis of Irish Registry patients was under-
taken, with clinical data abstracted from annual registry records (2008 through
2012). Variables of interest included hospitalisations, respiratory medications and
culture samples.
Over the ﬁve-year period, the annual frequency of hospitalisations increased from
a per-person average of 0.65 to 1.02. An increase was observed in the use of beta-
agonists (47.7−65.8%), rhDNase (32.3−45.7%), H2 receptor antagonists/proton-
pump inhibitors (28.5−41.2%) and nebulised hypertonic saline (3.1−44.9%) be-
tween 2008 and 2012 respectively. The per-person average of pulmonary exacer-
bations requiring IV antibiotics also increased from 0.9 to 1.3. Conversely, the
per-person average of cultured sputum specimens declined from 8.9 to 5.8.
Preliminary analysis of Irish CF Registry data suggests that temporal patterns in
service usage at CF centres/clinics may be emerging. Proﬁling health service usage
patterns may be useful for optimising the planning, ﬁnancing, and delivery of quality
care to patients with CF in the future.
Furthermore, CF-related services accessed by patients outside CF centres/clinics is
largely undocumented by CF registries. A pilot programme is underway to gather
and analyse community prescribing information between 2008 and 2012 to address
this gap in knowledge.
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